Roche receives U.S. FDA breakthrough therapy designation for ACTEMRA/RoACTEMRA in systemic sclerosis, and will present new study results at EULAR 2015

Roche today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) status to ACTEMRA/RoACTEMRA (tocilizumab) for systemic sclerosis (SSc).

http://www.roche.com/investors/updates/inv-update-2015-06-10.htm

Source: Roche Investor Update - June 10, 2015 Category: Pharmaceuticals Source Type: news

More News: Actemra | Food and Drug Administration (FDA) | Pharmaceuticals | Scleroderma | Study